Identification of immune subtypes of Ph-neg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib

Yang Hong, Ling Zhang, Xiaopeng Tian, Xin Xiang, Yan Yu, Zhao Zeng, Yaqing Cao, Suning Chen and Aining Sun

Abstract

Background: The clinical outcome of Philadelphia chromosome-negative B cell acute lymphoblastic leukemia (Ph-neg B-ALL) varies considerably from one person to another after clinical treatment due to lack of targeted therapies and leukemia's heterogeneity. Ferroptosis is a recently discovered programmed cell death strongly correlated with cancers. Nevertheless, few related studies have reported its significance in acute lymphoblastic leukemia.

Methods: Herein, we collected clinical data of 80 Ph-neg B-ALL patients diagnosed in our center and performed RNA-seq with their initial bone marrow fluid samples. Throughout unsupervised machine learning K-means clustering with 24 ferroptosis related genes (FRGs), the clustered patients were parted into three variant risk groups and were performed with bioinformatics analysis.

Results: As a result, we discovered significant heterogeneity of both immune microenvironment and genomic variance. Furthermore, the immune check point inhibitors response and potential implementation of Sorafenib in Ph-neg B-ALL was also analyzed in our cohort. Lastly, one prognostic model based on 8 FRGs was developed to evaluate the risk of Ph-neg B-ALL patients.

Conclusion: Jointly, our study proved the crucial role of ferroptosis in Ph-neg B-ALL and Sorafenib is likely to improve the survival of high-risk Ph-neg B-ALL patients.

Keywords: Ferroptosis, Acute lymphoblastic leukemia, Unsupervised clustering, Sorafenib, Immune

Background

B cell acute lymphoblastic leukemia (B-ALL) diagnosis and treatment had achieved remarkable improvement over the past decades. Thanks to the discovery of tyrosine kinase inhibitor (TKI), the survival of Philadelphia chromosome-positive B cell acute lymphoblastic leukemia was significantly prolonged [1]. However, more than 50% of B-ALL patients were negative in Philadelphia chromosome screening [2] and the prognosis of Philadelphia chromosome-negative B cell acute lymphoblastic leukemia (Ph-neg B-ALL) is heterogeneous [3]. Although chimeric antigen receptor T cells (CAR-T) therapy specifically targeting B cell antigens such as CD19 and CD22 benefited (for some cases) of refractory or relapsed B-ALL (R/R B-ALL), exhaustion and relapse of CAR-T after CAR-T therapy had limited its long-term efficiency [4]. Consequently, the exploration of new mechanisms involving Ph-neg B-ALL and therapeutic targets are crucially needed.
Ferroptosis was identified back in 2012 by Dixon [5], it is a form of cell death characterized by an overwhelming, iron-dependent accumulation of lethal lipids and reactive oxygen species (ROS) [6]. Several studies have confirmed that ferroptosis leads to tumor cells death and inhibits tumor growth [7–9]. On the other hand, apoptosis as another well-known form of cell death has been extensively investigated in the past 30 years while the clinical implementation of drugs targeting apoptosis regulators in cancers still faces some challenges [10]. Therefore, targeting recently identified ferroptosis processes might provide an efficient way to suppress tumor growth especially in tumors resistant to apoptosis inducers.

Although, understanding ferroptosis entirely is far from completely clear, researchers have identified several genes strongly correlated to ferroptosis progress. However, the core role of ferroptosis in Ph-neg B-ALL remained unclear. In this study, we aimed to explore the potential involvement of ferroptosis in the Ph-neg ALL patients with 24 ferroptosis related genes (FRGs) reported in the former research [11]. Primarily, we planned to evaluate prognostic significance of the FRGs in the Ph-neg ALL patients with unsupervised clustering and perform the bioinformatics-based analysis to reveal the mechanism of ferroptosis-involved genetic and biological heterogeneity. Secondly, whether the variant degrees of ferroptosis involvement correlated with immune microenvironment of leukemia was the other theme of our research for the emerging role of immune therapies in the field of cancers. Lastly, we expected to find out a certain kind of ferroptosis-inducers to treat high-risk Ph-neg ALL patients potentially.

Methods

Patients

A total of 80 patients diagnosed as de novo Ph-neg B-ALL were admitted in our center between October 2015 and January 2021. The Philadelphia chromosome identification was verified by both chromosome R-banding technique and fluorescence in situ hybridization (FISH). Additionally, we collected the enrolled patients’ initial bone marrow fluid samples from the clinical biological sample database of our center. Our study was approved by the ethics board of the First Affiliated Hospital of Soochow University and performed in agreement with the Declaration of Helsinki. All patients signed consent forms and the median follow-up time was 23.5 months.

Targeted gene mutational analysis

Genomic DNA was extracted from BM (Invitrogen) at the diagnosis phase and further processed as described in our previous report [12]. Summarily, targeted genomic sequencing of 172 leukemia recurrent mutated genes (listed in Table S2) was performed using the Ion S5 system (Personal Genome Machine, ThermoFisher, Grand Island, NY, USA) in 80 Ph-neg B-ALL patients and the trusted gene mutations were annotated after the filtration of synonymous and located variants outside coding sequence (CDS).

Whole transcription sequencing (RNA-seq) and data processing

To explore the potential mechanism related to the prognosis of Ph-neg B-ALL, we extracted total RNA with Trizol reagent and ensured the qualification of each RNA sample. Furthermore, total transcriptome RNA sequencing (RNA-seq) was performed with qualified extracted RNA samples. Concisely, we first established the library of each sample according to the protocol recommended by NEBNext Ultra RNA library Prep Kit for Illumina®. Subsequently, we quantified the libraries by both Qubit 3.0 and Agilent 2100, and then ensured the effective concentration of each library more than 10 nM through fluorescent quantitative PCR (qPCR). Lastly, these libraries were sequenced on the HiSeq sequencing platform after clustering by Hiseq PE Cluster Kit v4-cBot-HS.

To generate the gene expression data for the upcoming analysis, we filtered the raw sequencing data to remove joint sequences and bad-qualified results in the first step. Then the filtered data were annotated in the HISAT2 software with the reference file downloaded from ENSEMBL database (http://www.ensembl.org/index.html). Finally, reads count for each gene in the above samples was counted by HTSeq v0.6.0 and fragments per kilobase million mapped reads (FPKM) was then calculated to represent the expression level of genes in each sample. The formula is shown as: \( \text{FPKM} = \frac{10^{6} \times F}{NL/10^6} \) (F is the number of fragments in a certain sample that is assigned a certain gene, N is the total number of mapped reads in the certain sample and L is the length of the certain gene.)

Oncomine analysis

In the purpose of evaluate the ferroptosis role in B-ALL, we visited the Oncomine database (https://www.oncomine.org/resource) and performed the FRGs’RNA-level meta-analysis to the comparisons between the B-ALL samples and the normal controls in multiple B-ALL datasets [13–15]. The significance of FRGs variance was computed in the form of -log10 (P-value).

K-means clustering

K-means clustering is one of the most popular algorithms of unsupervised machine learning, processed with the Scikit-learn package V0.24.2 in Python V3.8, the FPKM values of 24 FRGs in 80 Ph-neg B-ALL samples were
standardized in the range of [0,1] before clustering to eliminate the influence of dimension and variation range. Thereafter, the dimension was reduced from 24 to 2 after the principal component analysis (PCA). Furthermore, the most significant K value was determined with the ‘elbow’ method. Eventually, a total of 80 samples were parted into variant groups according to the K-means clustering results. To assess the clustering models, we utilized the adjusted rand index (ARI), the adjusted mutual index (AMI), the V-measure score, the Fowlkes–Mallows index (FMI), the Silhouette Coefficient and the Calinski-Harabaz index.

**Immune characteristics of the sample clusters**

To investigate the variance of the immune infiltration in between the clusters, the RNA-seq data were processed with the CIBERSORTx algorithm [16]. A number 22 variant immune cells infiltration levels were calculated, and the results adequate with $P$-value < 0.05 were then adopted for further analysis. K means clustering was also used in the abovementioned way to divide 80 qualified samples into five components according to the immune infiltration results to demonstrate the feature differences among the three groups with variant degrees of risk. Five was chosen as the k-value to perform the clustering to ignore the immune cells with extremely low infiltration and to appear the making-up difference of the samples with diverse immune infiltration in the variant groups apparently. We further utilized the ESTIMATE algorithm to estimate the purity of the tumor, and the R package “estimate” for storm and the immune cells ratio, we then utilized ESTIMATE score to evaluate immune statement of leukemia’s micro-environment [17]. The cytolytic score generated from the average log10 value of five granzymes and perforin-1 (PRF1) gene expressions and the inflammatory score calculated in former reports [18, 19] were assembled to reveal the cytotoxic immune cell activity. The response to PD-1 blockage therapy was estimated according to a previous reported formula [20].

**Gene enrichment analysis**

Different expression genes (DEGs) amongst the sample clusters were calculated with R package “edgeR”. The Gene oncology and KEGG pathway enrichment were annotated with R packages “clusterProfiler” and “enrichplot” based on FDR < 0.05 and $|\log FC| > 2$ DEGs. The adjusted enriched terms at a $P$ value< 0.05 were then accepted. The Immune enrichment was calculated with package “ClueGO” using the Cytoscape software [21]. To explore the different involvement degree of ferroptosis, three modules of ferroptosis regulated genes (drivers, suppressors and markers) were downloaded from the FerrDb database [22] to merge with FDR<0.05 and $|\log FC| > 1$ DEGs.

**Sorafenib sensitivity evaluation**

The validated Sorafenib related genes established by former researches were downloaded from the Comparative Toxicogenomics Database (CTD) [23]. Six genes (FLT3 positively while the 5 genes left negatively correlated to the susceptibility to Sorafenib) were picked and the sum of the six genes log10 (FPKM) was defined as Sorafenib sensitivity score to evaluate the susceptibility to Sorafenib among variant sample clusters. To validate the efficiency of this score system, we utilized both gene expression data of 1457 common cell lines provided from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) (https://portals.broadinstitute.org/ccle) and half maximal inhibitory concentration (IC50) data of Sorafenib in multiple cell lines from the Genomics of Drug Sensitivity in Cancer (GDSC) [24].

**Development and validation of a prognostic model based on 8 FRGs**

To utilize the prognosis value of FRGs, we first employed a Cox regression analysis to calculate both hazard ratios (HRs) and $P$ values. FRGs that has a $P$ value < 0.1 was adopted for further analysis. Thereafter, the least absolute shrinkage and the selection operator (LASSO) Cox regression model were employed to narrow down the candidate genes and to develop the survival prediction model. As a final step, a total 8 FRGs along with their coefficients were retained, and the penalty parameter ($\lambda$) was limited by the minimum criteria. 70% of the samples were randomly selected to build the prediction model, while the 30% left was utilized as the validation cohort. The areas under curves (AUCs) of 1 year and 3 years survival were calculated with the R package ‘time ROC’. The Calibration curve was drawn to assess the efficiency of prediction. Subsequently, both the development and the validation cohorts survival were estimated by the Kaplan-Meier method and the difference significance in survival between high and low risk groups was evaluated by means of a stratified log-rank test.

**Statistical analysis**

All statistical analyses were completed using R software (v4.0.2), Graph Pad Prism 8.0 (GraphPad Inc., San Diego, CA, USA) and Python software (v3.8). We then administered a two-way Student T test to perform a numerical comparison and a Chi-square test to analyze the categorical data to compare the clinical and the molecular parameters between groups. Univariate Cox regression was conducted to determine factors with an independent prognostic value. Multivariate Cox regression model
was established as mentioned above. *P* value of < 0.05 was considered to be statistically significant and was presented as *P* < 0.05, **P* < 0.01, or ***P* < 0.001.

**Results**

**Expression characteristics of FRGs in ALL**

After performing the meta-analysis of the FRG-expressing difference between the B-ALL datasets and the datasets of normal controls in the Oncomine database, significant difference was noticed in 17 out of 24 FRGs (*P* < 0.05) indicating that the ferroptosis mechanism might play a potential role in the B-ALL development (Fig. 1A). In a more thorough way, the activity of the transferrin receptor (TFRC) and the permidine/spermine N1-acetyltransferase1 (SAT1) where the functions related the proferroptosis were significantly inhibited (Fig. 1B, C). Meanwhile, the cyclin-dependent kinase inhibitor1 (CDKN1A) and the farnesyl-diphosphatefarnesyltransferase 1 (FDFT1) expression were significantly enhanced which might promote an antiferroptotic effect (Fig. 1D, E).

**Variant risk clusters based on 24-FRGs expression**

Powered by K-means clustering, 80 Ph-neg B-ALL samples were divided into three variant risk clusters (Fig. 2A). Combined with our clinical follow-up data, three clusters had significant survival difference (*P* = 0.036) (Fig. 2B). The model evaluation through k varying from 2 to 10, k = 3 was noted as best k value in 3 out of 6 methods while the remaining methods indicated that k = 2 was acceptable as well (Fig. 2C-H). Consequently, 25 samples were clustered as the ‘High-risk’ group and 39 samples were included into the ‘Middle-risk’ group. The remaining 16 samples were defined as the ‘Low-risk’ group according to overall survival status.

**Clinical and genetic characteristics of Ph-neg B-ALL patients**

The included samples were clustered into a ‘High-risk’ group (n = 25), a ‘Middle-risk’ group (n = 39) and a ‘Low-risk’ group (n = 16) based on the K-means clustering results. The median age in all patients was 26 years old (range 9–56). After performing a systematic analysis of the clinical data, three groups had significant differences in their molecular alterations (*P* = 0.0269) while no apparent differences in the complete blood count (CBC), the bone marrow blasts ratio, the immunophenotyping and the chromosome karyotypes was noticed. Meanwhile, the treatment including CAR-T therapy and hematopoietic stem cell transplantation (HSCT) also had no major difference. Information in details was provided in Table S1.
Gene correlated to ferroptosis tended to mutate in the ‘high-risk’ group

In order to decipher the genomic varietal spectrum of Ph-neg B-ALLs, all patients in our study underwent Next Generation Sequencing (NGS) with a panel of 172 recurrent gene targets in hematologic malignancies. These variants were detected in 66 out of the 80 patients (82.5%) and the median number of variants per patient was 2 (range, 0–11). A total of 15 out of these 80 (18.8%) patients carried one, and 51 (28.8%) patients harbored two ($n = 23$), three ($n = 7$) or at least four ($n = 21$) variants. The most frequently mutated genes were NRAS ($n = 20$, 25.0%), KRAS ($n = 12$, 15.0%), SETD2 ($n = 10$, 12.5%), FLT3 ($n = 8$, 10.0%), PTEN11 ($n = 8$, 10.0%), and TP53 ($n = 8$, 10.0%).

Parted in three clusters, the ‘High-risk’ group contained 45 variant mutated genes; there were 35 and 20 different mutated genes in the ‘Middle-risk’ and the ‘Low-risk’ groups separately. Considering the coordination of gene mutations classified in these groups, there was also apparent heterogeneity. We defined the connection between two mutations in the same sample as one ‘edge’. As a result, the ‘High-risk’ group occupied 147 edges, while the ‘Middle-risk’ group and the ‘Low-risk’ groups included 67 and 26 edges separately.
Considering the differences in the group size, we standardized the results into 5.88 (High-risk), 1.72 (Middle-risk), and 1.63 (Low-risk) edges per mutation and demonstrated that more coordinated mutations existed in the ‘High-risk’ group than the other groups. After the horizon comparison of mutations in three groups, the classifications of mutations in the descending order were the single ‘High-risk’ group, the single ‘Middle-risk’ group, the ‘High-risk’ & ‘Middle-risk’ group, the ‘High-risk’ & ‘Middle-risk’ & ‘Low-risk’ group, the single ‘Low-risk’ group, the ‘Middle-risk’ & ‘Low-risk’ group and the ‘High-risk’ & ‘Low-risk’ group (Fig. 3B).

Due to the machine-learning clustering based on FRGs, the interfered genes correlated to ferroptosis were likely to be varying in the genomics among different groups. In order to validate our hypothesis, we acquired ferroptosis-correlated genes from the FerrDb. According to the Ferrdb classification, the genes were annotated as drivers, suppressors and markers. In details, the ferroptosis drivers are genes that promote ferroptosis. The ferroptosis suppressors are genes that prevent ferroptosis and...
the ferroptosis markers are genes that indicate the occurrence of ferroptosis. After merging our mutation data with the genes from the FerrDb, NRAS, KRAS, FLT3 and the CDKN2A, they were defined as the ferroptosis drivers (Fe-driver) while TP53 was defined as the ferroptosis suppressor (Fe-suppressor). The remaining mutation genes were named as Fe-negative genes since there was no sufficient evidence to connect them with ferroptosis. Upon gathering the mutation data, we surprisingly found that Fe-drivers and Fe-suppressors were the high recurrent gene mutations in our gene mutation detection panel (Fig. 3C). Further analysis indicated that the Fe-diver gene mutations existed in the ‘High-risk’ group were much more significant compared to those in the ‘Low-risk’ group after the scandalization with the sample counts ($P = 0.043$) (Fig. 3D).

Infiltrated immune cells difference among subgroups

Subsequently, we further explored the immune cell infiltration statement amongst the subgroups. Equipped with the CIBERSORTx method, 22 common immune cells were analyzed in 80 variant samples and excluded two samples where $P$ value failed to meet the acquisition of $< 0.05$ (Fig. 4A). In details, the B cells naive plasma cells, the T cells CD4 memory activated, the macrophage M0, the macrophage M2 and the neutrophils were significantly dissimilar between the ‘High-risk’ and the ‘Low-risk’ groups (Fig. 4B). Meanwhile, after comparing the ‘Middle-risk’ and the ‘Low-risk’ group, we found that B cells naïve, Plasma cells, T cells CD8, T cells CD4 memory resting enriched in ‘Middle-risk’ group and monocytes, macrophages M0, mast cells resting and neutrophils were enriched in the ‘Low-risk’ group (Fig. 4C). Furthermore, B cell naïve, T cells CD4 memory resting, T cells CD4 memory resting, T cell CD4 memory activated and macrophages M2 had significantly variant enrichment levels between the ‘High-risk’ and the ‘Middle-risk’ groups (Fig. 4D).

To demonstrate the correlation between the ferroptosis and the immune cells infiltration, the relationship between the 24 FRGs expressions and the infiltration degree of 21 variant types of immune cells expect resting dendritic cells undetected in all samples was calculated with the Pearson correlation coefficient (Fig. 4E). The results showed that the expression of SAT1 enabled the ferroptosis enhancement regulated by TP53 was found positive to the infiltration of neutrophils ($R = 0.816$) while negative to the infiltration of naïve B cells ($R = -0.584$) and plasma cells ($R = -0.519$).

In order to further describe the heterogeneity of the immune cell infiltration in general among the three groups, we clustered the 80 samples into five subtypes based on the infiltrative levels of the 22 variant types of immune cells in each sample (C1 to C5). Apparently, there was significant difference ($P < 0.000$) between ‘High-risk’ group and ‘Low-risk’ group. The difference between the ‘Middle-risk’ and the ‘Low-risk’ group was also significant ($P = 0.001$). C2 was mainly enriched in the ‘High-risk’ and the ‘Middle-risk’ groups while C3 was enriched in the ‘Low-risk’ group. More information on the heterogeneity of the immune infiltration amongst groups was shown in Fig. 4F.

Immune characteristics and response to immune checkpoint inhibitors (ICIs) among subgroups

With immune therapy cropping up in cancer therapy, the investigation aiming at tumor micro environment revealed expected values. After analyzing DEGs with ‘ClueGo’ package in Cytoscape software v3.8, the differences between the ‘High-risk’ and the ‘Low-risk’ groups mainly enriched in neutrophil activation, neutrophil migration, positive regulation of neutrophil degranulation, negative regulation of leukocyte chemotaxis and macrophage activation immune signal pathways (Fig. 5A). On the other hand, the comparison between the ‘Middle-risk’ and the ‘Low-risk’ groups, neutrophil degranulation, complement receptor activity, neutrophil-mediated killing of symbiont cell and macrophage activation immune signal pathways were mainly enriched (Fig. 5B).

‘ESTIMATE’ R package was an ideal tool to describe the immune statement of cancers based on gene transcription data. After processing the gene expression data of 80 samples with ‘ESTIMATE’ algorithm, the stromal score, the immune score and the tumor purity were calculated. The ‘Low-risk’ group ranked significantly higher in stromal score, immune score and lower tumor purity compared to the ‘High-risk’ and the ‘Middle-risk’ groups (Fig. 5C-E). These results suggested that the ‘High-risk’ and the ‘Middle-risk’ groups had relatively fewer immune cells in tumor micro-environment (TME) which benefited for the living of leukemia.
Fig. 4 (See legend on previous page.)
Furthermore, the function of T cells attacking against leukemia with cytolytic score and inflammatory score was estimated. There were significant differences in cytolytic scores and inflammatory scores between ‘High-risk’ and ‘Low-risk’ groups (Fig. 5F, G) suggesting the malfunction of T cells in TME as one explanation of the relatively poor prognosis of the ‘High-risk’ groups. Oppositely, the HLA expression was often reduced in cancers for escaping the immune surveillance. In our study, the HLA expression (including HLA-A, B, C) was relatively lower in the ‘High-risk’ and the ‘Middle-risk’ group compared to the ‘Low-risk’ group (Fig. 5H).

Immune checkpoint inhibitors (ICIs) have been recognized as a promoting therapy in solid tumors. However, the role of ICIs in leukemia is still doubtful. Referred to the IFN-γ signature and expanded immune signature among three groups which indicated the patients from variant groups had the similar responses to PD-1 blockers

Significant differences in gene enrichment analysis
In an attempt to explore the mechanism of ferroptosis influencing the prognosis of Ph-neg B-ALL patients, we merged the DEGs between any two groups with the ferroptosis correlated genes from FerrDb (Fig. 6A). As expected, the most notable result was that the ferroptosis correlated genes tended to enrich in the comparison between the ‘High-risk’, the ‘Middle-risk’, and the ‘Low-risk’ groups (Fig. 6B). Furthermore, the ferroptosis driver genes were the dominant genes in enriched ferroptosis...
Fig. 6 Ferroptosis and GO/KEGG pathway enrichment of DEGs. **A** The different expression genes (DEGs) (|logFC| > 1, FDR < 0.05) resulted from the comparison among three variant risk clusters through the R package edgeR were merged with ferroptosis regulated genes from FerrDb to do the ferroptosis enrichment. **B, C** Compared to the DEGs between the ‘Middle-risk’ (M-r) and the ‘Low-risk’ groups (L-r), there were more ferroptosis regulated genes enriching in the DEGs between the ‘High-risk’ (H-r) or ‘Middle-risk’ (M-r) and the ‘Low-risk’ groups. Meanwhile, in three types of ferroptosis regulated genes, ferroptosis driver genes were dominant in the results of L-r vs. H-r while ferroptosis marker genes were the main component after the comparison between L-r and M-r. **D, E** The GO and KEGG pathway enrichment of DEGs (|logFC| > 2, FDR < 0.05) between ‘High-risk’ group and ‘Low-risk’ group. **F, G** The GO and KEGG pathway enrichment of DEGs (|logFC| > 2, FDR < 0.05) between ‘Middle-risk’ group and ‘Low-risk’ group.
correlated genes when compared with ‘High-risk’ and ‘Low-risk’ groups. Meanwhile, as a result of the comparison between the ‘Middle-risk’ and the ‘Low-risk’ groups, ferroptosis marker genes were the most dominant. The equal number of ferroptosis correlated genes in the DEGs between ‘High-risk’ and ‘Middle-risk’ groups (Fig. 6C).

Gene oncology (GO) and KEGG pathway enrichment of DEGs were performed between the ‘High-risk’, ‘Middle-risk’, and ‘Low-risk’ groups. In the enrichment results between ‘High-risk’ and ‘Low-risk’ groups, biological process (BP) term ‘neutrophil activation’, cellular components (CC) term ‘tertiary granule’, and molecular function (MF) ‘immune receptor activity’ were the most trusted GO term (Fig. 6D). Meanwhile, ‘Hematopoietic cell lineage’ was the most trusted KEGG pathway term (Fig. 6E). Correspondingly, the biological process (BP) ‘neutrophil degranulation’, cellular components (CC) ‘specific granule’, molecular function (MF) ‘carbohydrate binding’ and KEGG pathway ‘Staphylococcus aureus infection’ terms were the most significantly enriched terms in the results when comparing the ‘Middle-risk’ and the ‘Low-risk’ groups (Fig. 6F, G).

Identification of the potential implementation of Sorafenib in ‘high-risk’ Ph-neg B-ALL

Since Sorafenib is proved as a drug that is able to induce ferroptosis in cancers and also being implemented in the treatment of AML, we further explored the potential implement of Sorafenib in ALL.

Firstly, we compared the Sorafenib related genes acquired from the CTD database between ‘High-risk’ and ‘Low-risk’ groups. The comparison of the Sorafenib related genes between ‘Middle-risk’ and ‘Low-risk’ groups was done in the same way. After the comparisons, the genes which expressed highly in both the ‘High-risk’ and the ‘Middle-risk’ groups were ranked as the up-regulated genes. Meanwhile, the genes expressed highly in the ‘Low-risk’ group in the both comparisons were defined as the down-regulated genes. The rest Sorafenib related genes were classified as the not-significant genes. As a result, we totally acquired 31 up-regulated genes (red, \( P < 0.05 \)), 56 down-regulated genes (green, \( P < 0.05 \)) and 45 not-significant genes (blue, \( P \geq 0.05 \)). High-confidence interaction score ( \( > 0.9 \)) Protein-Protein Interaction analysis (PPI) of these Sorafenib correlated genes were performed referred to STRING database (http://string-db.org/) (Fig. 7A).

Afterwards, we selected six genes involved in the susceptibility of Sorafenib. They were FLT3 positively correlated to the sensitivity of Sorafenib and MAPK1, MAPK3, GADD45G, MCL1, PINK1 and negatively related to the sensitivity of Sorafenib. Their expression differences between three groups were shown in Fig. 7B-G. In order to speculate the sensitivity of Sorafenib by combining these factors, we calculated the Sorafenib sensitivity score using the equation: \( \log_{10} (\text{FLT3})-\log_{10} (\text{MAPK1})-\log_{10} (\text{MAPK3})-\log_{10} (\text{GADD45G})-\log_{10} (\text{MCL1})-\log_{10} (\text{PINK1}) \). Intriguingly, compared to ‘Low-risk’ group, ‘High-risk’ and ‘Middle-risk’ groups were ranked as higher scores which indicated Ph-neg B-ALL patients in ‘High-risk’ or ‘Middle-risk’ groups may be susceptible to the treatment with Sorafenib (Fig. 7H).

In the aim of verifying the efficiency of our established Sorafenib sensitivity score, we downloaded six gene expression data of the ALL cell lines NALM-6, SUP-B15 and 697 from CCLE database (Fig. 7I) and then calculated the Sorafenib sensitivity score of the three lines. Correlated the real sensitivity in IC50 of these cell lines on GDSC database, we surprisingly found that with the increasing of Sorafenib Sensitivity Score, the IC50 of these cell lines decreased. These data proved that our score system was an effective tool to assess the susceptibility of Sorafenib and Sorafenib may help to reverse the poor prognosis of Ph-neg B-ALL patients in ‘High-risk’ and ‘Middle-risk’ groups.

FRGs-based model in help of survival evaluation of Ph-neg B-ALL

As our previous analysis had demonstrated that the 24 FRGs enabled to cluster the Ph-neg B-ALL samples into variant-risk groups, univariate Cox regression was further employed to screen the FRGs influencing survival (Fig. 8A). The 8 genes (ALOX15, ATP5G3, CARS, CDKN1A, LPCAT3, SAT1, SLC1A5 and TFRC) that met the criteria of \( P < 0.1 \) were retained for modeling. The correlation between the 8 genes and the parameters of the former K-means clustering were displayed in the form of heat map (Fig. 8B). Through employing the LASSO Cox regression analysis, an 8-gene signature was constructed referred to the optimum \( \lambda \) value (Fig. 8C, D). Time-dependent receiver operating characteristic (ROC) was adopted as a classical method to evaluate the sensitivity and the specificity of the prognostic models. After calculating, the AUC was 0.716 for 1 year and 0.924 for 3 year in the development cohort (Fig. 8E). On the other hand, the calibration curve was utilized to evaluate a 3-year prediction efficiency of our established 8-gene multivariate Cox regression model (Fig. 8F). In the end, our model enabled to distinguish samples of favorable and poor prognosis in both development and validation groups after Kaplan-Meier analysis (Fig. 8G, H).

Discussion

In this study, we retrospectively collected clinical data of 80 Ph-neg B-ALLs treated in our center and the results revealed that the combination of 24 FRGs
expressions enabled to cluster these patients into three groups using the unsupervised machine learning algorithm Kmeans clustering. Moreover, there was a significant correlation between the immune microenvironment and FRG-based clustering. In addition, the variant frequency of the ferroptosis regulated gene mutations among these groups and the gene functional enrichment mechanism were explored to explain these differences. Based on our findings on the ferroptosis related heterogeneity among the groups, we speculated and validated that Sorafenib might be an effective drug to improve the poor prognosis of high-risk Ph-neg B-ALLs.

Ferroptosis is a recently discovered programming death in the characteristics of cell membrane damage due to the GPX4 loss of activity and the intracellular accumulation of lipid reactive oxygen [25]. Accumulated evidence showed that the ferroptosis widely participates in tumorigenesis and plays a promoting role in tumor therapy [26, 27]. However, there is a lack of studies highlighting ferroptosis in B cell acute lymphoblastic leukemia. Moreover, the outcome of Ph-neg B-ALL after treatment was broadly variant due to lack of targeted therapy like imatinib in Philadelphia positive ALL. Here, we employed NGS technology to explore the heterogeneity in both genetic and transcriptional levels of Ph-neg B-ALLs with
24 FRGs. Not only did we identify the expression of FRGs in ALL were widely different from the normal people, but we also established that the combination of FRGs expression had the ability to recognize variant risk groups of Ph-neg B-ALL powered by K-means clustering. These results were the clinical reflection of evidences that the progression of leukemia is highly reliant on iron which maintains the rapid growth rate of leukemia cells [28–30].

Emerging immune check checkpoint inhibitors (ICIs) based therapy raised our attention to investigate the leukemia’s immune microenvironment. However, the manner which the ferroptosis mechanism involves in leukemia immune microenvironment still in need for more research, our results have indicated the microenvironment aberrance accompanied by ferroptosis difference. Compared to the ‘Middle-risk’ and the ‘Low-risk’ groups; there was more B cells naïve infiltration related with higher burden of leukemia in ‘High-risk’ groups. Moreover, CD4+ memory activated T cells significantly decreased in the ‘High-risk’ groups; it may attenuate the ferroptosis of leukemia induced by cytotoxic T cells according to previous reports [31]. In addition, the polarization of macrophages to an M2 phenotype was significantly outstanding in the ‘High-risk’ group. This phenomenon may involve in ferroptosis and lead to stimulate leukemia growth ultimately [32]. Furthermore, since there was little known about the role of ICIs in ALL, our research indicated that there was no

Fig. 8 The development and validation of survival predicted model based on 8 FRGs. A Univariate Cox regression analysis of 24 FRGs. B Correlation between PCA1/2 and 8-survival correlated FRGs. C LASSO regression of the 8 survival-correlated FRGs. D Cross-validations for tuning the parameter selection in the LASSO regression. E, F Both ROC curves and the calibration demonstrated the predictive efficiency of the model. G, H Kaplan–Meier curves for the overall survival of variant risk patients from the development cohort and the validation cohort.
potentially higher benefits from PD-1 blockade therapy in the ‘High-risk’ or ‘Middle-risk’ groups compared to the ‘Low-risk’ group. These results raised the idea of the implementation of ferroptosis inducers in the ‘High-risk’ and the ‘Middle-risk’ groups which involved low immune cell infiltration. For one thing, leukemia microenvironment with low immune cell infiltration facilitates the leukemia to escape the surveillance of the immune system [33]. On the other hand, the inflammatory environment induced by ferroptosis inducers plays the chemotaxis effect to immune cells and changes the ‘cold’ leukemia to the ‘hot’ leukemia which is vulnerable to the chemo-therapy.

One of the reasons why ferroptosis closely participated in Ph-neg B-ALL is it has relatively high frequency of RAS and TP53 gene mutations which was involved in ferroptosis [34–36]. Based on these findings, the mutation of ferroptosis driver genes were significantly concentrated in the ‘High-risk’ group which may induce the ferroptosis resistance to leukemia. To demonstrate our hypothesis, we chose Sorafenib as the promoting curable drug for its ferroptosis inducing effect [37] and successful implementation in FLT3-ITD positive AML [38]. In past studies, Sorafenib was found to induce ferroptosis mainly by inhibiting the activity of system xc- and not necessarily on the inhibition of its kinase targets [37, 39, 40]. However, there were few reported clinical trials of Sorafenib in Ph-neg B-ALL patients. In our investigation, it was surprising to point that patients from the ‘High-risk’ and the ‘Middle-risk’ groups based on gene expression were predicted to be more sensitive to Sorafenib possibly owing to variant degrees of ferroptosis involvement in Ph-neg B-ALL. Based on these interesting findings, we will further to initiate a clinical trial to verify the curable effect of Sorafenib combined with chemotherapy in high-risk Ph-neg B-ALLs.

Comparable to other models correlated with ferroptosis in other types of cancers [11, 41], we systematically investigated the ferroptosis involvement in our samples and proved that the ferroptosis plays an important but still an undiscovered role in Ph-neg B-ALL. Although the prognosis of Philadelphia positive B-ALL patients became favorable thanks to the invention of imatinib, a newly discovered and complex biological process which needs to be further investigated. In addition, due to the rapid improvement in B-ALL treatment, especially after the coming of CAR-T therapy, we faced limited cases to analyze the importance of ferroptosis in Ph-neg B-ALL patients and the exploration of ferroptosis seemed to be meaningful in the new age since some patients enrolled in our study had received CAR-T therapy. Consequently, our study based on the current knowledge and data mining might need further updates and more validations in researches to come.

Conclusion

In summary, after the exploration the potential role of ferroptosis in Ph-neg B-ALL with the clinical data and the RNA-seq results of 80 Ph-neg B-ALL treated in our center. Not only did we demonstrated the combination of expression of FRGs enabled to cluster Ph-neg B-ALL patients into variant risk groups, but also analyzed their correlation with leukemia’s immune microenvironment and gene mutation characteristics. Based on these findings, we further raised the potential implementation of Sorafenib in high-risk Ph-neg ALL patients. Moreover, a Cox regression model based on 8 FRGs was established to help evaluate the prognosis of Ph-neg B-ALL patients. Overall, our research put forward a new view to understand the pathogenesis of Ph-neg ALL and evaluate the involved patients.

Abbreviations

Ph-neg B-ALL: Philadelphia chromosome-negative B cell acute lymphoblastic leukemia; FRG: Ferroptosis related gene; TKI: Tyrosine kinase inhibitor; B-ALL: B cell acute lymphoblastic leukemia; CAR-T: Chimeric antigen receptor T cells; R/R ALL: Refractory or relapse acute lymphoblastic leukemia; ROS: Reactive oxygen species; FISH: Fluorescence in situ hybridization; RNA-seq: Whole transcriptome sequencing; qPCR: Fluorescent quantitative polymerase chain reaction; FPKM: Fragments per kilobase million mapped reads; CDS: Coding sequence; PCA: Principal component analysis; ARI: Adjusted rand index; AMI: Adjusted mutual index; FMI: Fowlkes–Mallows index; DEG: Different expression gene; CTD: Comparative Toxicogenomics Database; CLE: Broad Institute Cancer Cell Line Encyclopedia; ICSO: Half maximal inhibitory concentration; GDSC: Genomics of Drug Sensitivity in Cancer; HR: Hazard ratio; AUC: Area under curve; LASSO: Least absolute shrinkage and selection operator; CBC: Complete blood count; HSCT: Hematopoietic stem cell transplantation; NGS: Next generation sequencing; GO: Gene ontology; PPI: Protein-protein interaction analysis; ROC: Receiver operating characteristic.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12885-021-09076-w.

Additional file 1: Table S1. Baseline clinical characteristics of Ph-neg B-ALL patients according to K-means clustering.
Acknowledgements
The authors would like to acknowledge Prof. Jianhong Chu from The Institute of Bone Marrow Transplantation for his constructive comments on immune analysis.

Authors’ contributions
YH and XPT contributed to the concept development and study design and wrote the manuscript. LZ, YY and XX collected the clinical data and followed up the enrolled patients. XPT, YQC and ZZ were carried out the laboratory experiments. YH and LZ performed the data check and analysis. SNC and ANS participated in the figure preparation and revision of the paper. All authors read and approved the final manuscript.

Funding
This work was supported by grants from the National Natural Science Foundation of China (grant no. 81873449). The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The gene expression data in the form of FPKM values analyzed during the current study are attached in the additional supporting file (matrix_for_analysis.txt).

Declarations

Ethics approval and consent to participate
This study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee and Institutional Review Board of The First Affiliated Hospital of Soochow University, Suzhou, China. Consent for publication
Signed consents for publication were obtained from patients whose data were used in this manuscript.

Competing interests
The authors declare no conflict of interest.

Author details
1 Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou, China. 2 Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

Received: 30 May 2021 Accepted: 30 November 2021

Published online: 14 December 2021

References
1. Abou Dalle I, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Treat Options in Oncol. 2019;20(1):4.
2. Burmeister T, et al. Patients’ age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008;112(3):918–9.
3. Jabbour E, et al. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia: a single-arm, phase 2 trial. Lancet Haematol. 2020;7(7):e523–33.
4. Huang R, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13(1):86.
5. Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72.
6. Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10(1):9–17.
7. Ma S, et al. Ferroptosis is induced following siroasine and lipasinib treatment of breast cancer cells. Cell Death Dis. 2016;7:e2307.
8. Yamauchi Y, Kasukabe T, Kumakura S. Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. Int J Oncol. 2018;52(3):1011–22.
9. Truillo-Alonso V, et al. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nanotechnol. 2019;14(6):616–22.
10. Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395–417.
11. Liu Z, et al. Systematic analysis of the aberrances and functional implications of ferroptosis in cancer. iScience. 2020;23(7):101302.
12. Yu Y, et al. Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes. Leuk Lymphoma. 2020;61(4):919–26.
13. Andersson A, et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia. 2007;21(6):1198–203.
14. Maia S, et al. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res. 2005;65(21):10050–8.
15. Haferlach T, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol. 2010;28(15):2529–37.
16. Newman AM, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.
17. Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
18. Rooney MS, et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(2–4):48–61.
19. Wu F, et al. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma. J Pathol. 2020;251(3):272–83.
20. Ayers M, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–40.
21. Shannon P, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.
22. Zhou N, Bao J. FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020;2020:bava021.
23. Davis AP, et al. CTD anatomy: analyzing chemical-induced phenotypes and exposures from an anatomical perspective, with implications for environmental health studies. Curr Res Toxicol. 2021;2:128–39.
24. Yang W, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955–61.
25. Mou Y, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34.
26. Bersuker K, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688–92.
27. Chu B, et al. ALOX12 is required for p53-mediated tumour suppression through a distinct ferroptosis pathway. Nat Cell Biol. 2019;21(5):579–91.
28. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13(5):342–55.
29. Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk— a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidemiol Biomark Prev. 2014;23(1):12–31.
30. Manz DH, et al. Iron and cancer: recent insights. Ann N Y Acad Sci. 2016;1368(1):149–61.
31. Wang W, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4.
32. Dai E, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16(11):2069–83.
33. Chen LY, et al. Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia. Transl Oncol. 2020;13(11):100838.
34. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234–45.
35. Schott C, et al. Oncogenic RAS mutants confer resistance of RMS13 rhabdomyosarcoma cells to oxidative stress-induced ferroptotic cell death. Front Oncol. 2015;5:131.
36. Jiang L, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57–62.
37. Lachaer E, et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. Anticancer Res. 2014;34(11):6417–22.
38. Wu M, Li C, Zhu X. FLT3 inhibitors in acute myeloid leukemia. J Hematol Oncol. 2018;11(1):133.
39. Sun X, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63(1):73–84.
40. Dixon SJ, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife. 2014;3:e02523.
41. Wu G, et al. A new survival model based on ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma. Aging (Albany NY). 2020;12(14):14933–48.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.